Elevated aldosterone causes a moderate to severe increase in blood pressure, and leads to various target organ damage including cardiovascular ones. Aldosterone has been considered one of the important risk factors for cardiovascular and cerebrovascular diseases. Currently, the use of mineralocorticoid receptor antagonists (MRA) has been proven to reduce blood pressure levels, but long-term prognostic data are lacking in hypertensive patients. Therefore, the purpose of this clinical trial is to assess the effect of MRA on cardiovascular disease in patients with Hypertension and Hyperaldosteronemia.
Clinical Study
Summary
Study Name: Effect of MRA on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia (EMRACVDHHA)
Status: Enrolling by invitation
Conditions: Hypertension, Hyperaldosteronemia (hyperaldosteronism)
Interventions: Drug: Spironolactone. Drug: Finerenone. Other: Blank control
Locations: People’s Hospital of Xinjiang, Uygur Autonomous Region, China
Study link: https://clinicaltrials.gov/ct2/show/NCT05688579
To search for other studies by topic, location, or status, go to our Clinical Studies page.
